Skip to main content
. 2021 May 28;30(11):1662–1674. doi: 10.1111/exd.14390

FIGURE 2.

FIGURE 2

Hyperplasia reduction and epidermal architecture recovery after FIB‐116 application on ear skin of DKO* mice. (A) Representative immunofluorescence images of ear section from control (WT), DKO* without treatment, DKO*‐Amygdalin, DKO*‐Vehicle mice after 14 days of treatment. Green (Keratin 5), Red (Involucrin) and blue (Dapi). Aberrant expression of the basal layer protein K5 in suprabasal epidermal layers in DKO* and DKO*‐vehicle mice, whereas animals treated with amygdalin cream rescue the expression of K5 mainly in the basal layer. Involucrin, a corneal layer protein, increases in animals treated with amygdalin cream while its expression is disrupted in DKO* and DKO‐vehicle mice. n = 3 per group. Dotted lines separate epidermis and dermis. (B) Quantification analysis of proliferative marker Ki67 in ear skin of control (WT), DKO* without treatment, DKO*‐Amygdalin, DKO*‐Vehicle mice after 14 days of treatment. n = 3 per group. Statistical significance *p < 0.05 (t‐student two‐tailed test relative to controls and vehicle group)